Abstract
Lymphoma patients and patients suffering from chronic renal diseases exhibit an increased risk for pneumococcal infections. Therefore, vaccination with the polyvalent pneumococcal vaccine of such patients is recommended (1). This pneumococcal vaccine consists of purified capsular polysaccharides prepared from 23 types of Streptococcus pneumoniae. A “protective antibody level” is still not clearly defined. For routine estimations, we assume an at least fourfold rise in antibodies to the 23-valent vaccine as a positive immune response when measured in an ELISA using the derivatized whole vaccine as antigen four weeks post immunization as compared with the preimmunization level. Antibodies developed to individual capsular polysaccharides and to the cell wall polysaccharide (discussed as a contaminant of the vaccine) were estimated to compare their relative immunogenicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
